Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

By K. Lindor, Kris V. Kowdley, E. Heathcote, M. E. Harrison, R. Jorgensen, P. Angulo, J. Lymp, L. Burgart, P. Colin. Hepatology, 2004

714 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/f6f05d4649d4d77a7f65a6f5664fc0cc41126772

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. Herbert Tilg
4. K. Cusi
5. A. Sanyal
6. E. Brunt
7. C. Day
8. S. Bellentani

In Hepatology

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. E. Brunt
6. A. Diehl
7. Y. Sumida
8. M. Yoneda

Citations in the corpus

• Current and future pharmacological therapies for NAFLD/NASH (2017, background): “According to a large, multicenter RCT, standard dose of UDCA has no effects on liver histology in NASH [23], although some studies suggest that high dosage of this agent may show a favorable effect.”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Ursodesoxycholic acid alone did not show a consistent biochemical and histological benefit at the dose of 13–15 mg/kg [218,219]; higher doses (30 mg/kg) induced a significant reduction in aminotransferase values, although it is uncertain whether this translates into histological improvement [220].”
• Dietary lipids, gut microbiota and lipid metabolism (2019, result): “One example is UDCA, which has been shown to have beneficial impact on steatosis and serum lipid levels after short-term treatment in severely obese patients [69] while others have reported negative results regarding improvement of NASH in response to UDCA treatment [84, 85].”
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, background): “Notably, a single large multicenter RCT convincingly showed that UDCA offers no histological benefit over placebo in patients with NASH.(139) Omega-3 fatty acids, currently approved in the United States to treat hypertriglyceridemia, have been investigated to treat NAFLD both in animal models and in”
• Inflammatory Mechanisms in the Regulation of Insulin Resistance (2008, background): “It has to be mentioned that concentrations used—for example, for UDCA—were approximately ten times higher (118) than those achieved in humans and treatment of patients with nonalcoholic steatohepatitis with UDCA so far has not been successful (119).”